CF
OKUR

Cantor Fitzgerald’s OnKure Therapeutics OKUR Stock Holding History

Cantor Fitzgerald’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$456K Buy
100,014
+114
+0.1% +$489 ﹤0.01% 289
2026
Q1 		$414K Sell
99,900
-345,178
-78% -$1.07M 0.01% 227
2025
Q4 		$1.29M Sell
445,078
-46,785
-10% -$140K 0.02% 149
2025
Q3 		$1.35M Sell
491,863
-177,676
-27% -$440K 0.01% 189
2025
Q2 		$1.6M Buy
669,539
+538,839
+412% +$1.41M 0.03% 123
2025
Q1 		$562K Buy
130,700
+95,000
+266% +$534K 0.01% 144
2024
Q4 		$294K Buy
+35,700
New +$540K 0.01% 150

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cantor Fitzgerald's OKUR Position: Q2 2026 in Review

Cantor Fitzgerald increased its OnKure Therapeutics (OKUR) stake by 0.11% in Q2 2026, buying an estimated $489 and bringing the position to 100,014 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #289.

Cantor Fitzgerald first reported a position in OKUR in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.6M in Q2 2025. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Cantor Fitzgerald held 100,014 shares of OnKure Therapeutics worth $456K as of Q2 2026.
  • Cantor Fitzgerald bought 114 OnKure Therapeutics shares in Q2 2026, an estimated $489.
  • OnKure Therapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q2 2026, its #289 holding.
  • Cantor Fitzgerald first reported a position in OnKure Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Cantor Fitzgerald's OnKure Therapeutics position peaked at $1.6M in Q2 2025.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.